Table 1B.
Baseline characteristics of critical patients with AMI stratified by the CONUT score in the American MIMIC-III database.
| MIMIC | %, Std.Diff | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristics | Overall (n = 887) | Absent (n = 182) | Mild (n = 369) | Moderate (n = 271) | Severe (n = 65) | P-value | Absent vs. mild | Absent vs. moderate | Absent vs. severe |
| Demographic characteristics | |||||||||
| Age, year | 70.1 ± 12.9 | 64.1 ± 13.5 | 70.6 ± 12.6 | 73.0 ± 12.0 | 71.9 ± 11.5 | <0.001 | 49.7 | 69.5 | 62.2 |
| Female, n (%) | 332 (37.4) | 67 (36.8) | 134 (36.3) | 101 (37.3) | 30 (46.2) | 0.505 | 1.0 | 0.9 | 19.0 |
| Complication | |||||||||
| CHF, n (%) | 428 (48.3) | 62 (34.1) | 176 (47.7) | 156 (57.6) | 34 (52.3) | <0.001 | 28.0 | 48.5 | 37.5 |
| CKD, n (%) | 447 (50.4) | 51 (28.0) | 179 (48.5) | 172 (63.5) | 45 (69.2) | <0.001 | 43.1 | 76.1 | 90.5 |
| Anemia, n (%) | 542 (61.1) | 64 (35.2) | 215 (58.3) | 208 (76.8) | 55 (84.6) | <0.001 | 47.6 | 92.3 | 116.9 |
| Hypertension, n (%) | 437 (49.3) | 107 (58.8) | 195 (52.9) | 117 (43.2) | 18 (27.7) | <0.001 | 12.0 | 31.6 | 66.1 |
| Diabetes, n (%) | 309 (34.8) | 52 (28.6) | 135 (36.6) | 100 (36.9) | 22 (33.9) | 0.243 | 17.2 | 17.8 | 11.4 |
| Stroke, n (%) | 95 (10.7) | 15 (8.2) | 39 (10.6) | 31 (11.4) | 10 (15.4) | 0.423 | 8.0 | 10.8 | 22.3 |
| STEMI, n (%) | 329 (37.1) | 70 (38.5) | 146 (39.6) | 87 (32.1) | 26 (40.0) | 0.237 | 2.3 | 13.3 | 3.2 |
| PCI, n (%) | 292 (33.8) | 65 (36.3) | 126 (35.5) | 82 (30.9) | 19 (29.2) | 0.469 | 1.7 | 11.4 | 15.1 |
| Pre-AMI, n (%) | 2 (0.2) | 0 (0.0) | 1 (0.3) | 1 (0.4) | 0 (0.0) | 0.84 | 7.4 | 8.6 | 0.0 |
| Laboratory tests | |||||||||
| Albumin, g/L | 34.16 ± 5.74 | 39.13 ± 3.32 | 35.91 ± 3.82 | 30.76 ± 4.76 | 24.43 ± 3.46 | <0.001 | 89.9 | 204.1 | 433.1 |
| Lymphocyte, 10*9/L | 1.37 (0.91, 2.06) | 2.11 (1.72, 2.79) | 1.39 (1.02, 2.04) | 1.02 (0.72, 1.46) | 0.78 (0.47, 1.11) | <0.001 | 44.7 | 68.2 | 81.5 |
| Cholesterol, mmol/L | 3.94 ± 1.25 | 5.04 ± 0.97 | 4.01 ± 1.05 | 3.37 ± 1.17 | 2.83 ± 0.94 | <0.001 | 103.0 | 155.6 | 231.8 |
| K+, mmol/L | 4.26 ± 0.76 | 4.10 ± 0.64 | 4.26 ± 0.73 | 4.36 ± 0.86 | 4.29 ± 0.78 | 0.005 | 23.8 | 34.3 | 26.2 |
| Na+, mmol/L | 138.33 ± 4.18 | 138.81 ± 3.00 | 138.16 ± 4.08 | 138.44 ± 4.78 | 137.49 ± 4.69 | 0.117 | 18.3 | 9.3 | 33.6 |
| WBC, 10*9/L | 12.53 ± 6.06 | 12.33 ± 5.80 | 12.08 ± 5.57 | 12.91 ± 6.45 | 14.06 ± 7.43 | 0.058 | 4.5 | 9.5 | 25.8 |
| Medications | |||||||||
| ACEI or ARB, n (%) | 572 (64.5) | 116 (63.7) | 257 (69.7) | 170 (62.7) | 29 (44.6) | 0.001 | 15.2 | 7.0 | 6.7 |
| Beta blocker, n (%) | 778 (87.7) | 167 (91.8) | 332 (90.0) | 230 (84.9) | 49 (75.4) | 0.001 | 8.9 | 5.6 | 18.4 |
| Statins, n (%) | 726 (81.9) | 158 (86.8) | 315 (85.4) | 207 (76.4) | 46 (70.8) | 0.001 | 19.9 | 18.3 | 1.7 |
| Antiplatelet, n (%) | 501 (56.5) | 115 (63.2) | 218 (59.1) | 142 (52.4) | 26 (40.0) | 0.004 | 19.6 | 17.3 | 3.0 |
| CCB, n (%) | 189 (21.3) | 22 (12.1) | 89 (24.1) | 62 (22.9) | 16 (24.6) | 0.008 | 5.2 | 8.1 | 32.4 |
CHF, congestive heart failure; CKD, chronic kidney disease; STEMI, ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; LYM, lymphocyte; K+, potassium ion; Na+, sodium ion; WBC, white blood cell; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium blocker.